Psoriasis Clinical Trial
Official title:
Comparing Mindfulness Based Cognitive Therapy and Mindfulness Based Self-compassion Therapy: Understanding What Works Psychologically and Physiologically in a Randomized Study in Dermatology
Increasing research evidence supports the effectiveness of mindfulness based interventions;
however, the exact mechanisms of change are poorly understood. Some evidence proposes that
self-compassion is an important mechanism of change in the effectiveness of mindfulness
based interventions. The current research will evaluate and compare the effectiveness of two
mindfulness meditation approaches; Mindfulness Based Cognitive Therapy (MBCT) and
Mindfulness based Self-compassion Therapy (MBSCT), for individuals with psoriasis, a skin
condition commonly associated with stress. Blood analyses will be conducted to assess and
compare the impact of the interventions on the immune system. Self-report questionnaires
will explore participants' psychological functioning (e.g. self-compassion, depression,
anxiety, worry). This study will also examine whether a relationship exists between immune
functioning and psychological factors. An audio-guided MBSCT programme will be piloted, with
a view to trialling as a more cost-effective alternative to traditional mindfulness
interventions. Findings will enable us to design more effective interventions in the future,
and yield clear results regarding the existence of a definite link between immunological
functioning and psychological functioning.
The main research hypothesis is that participants who complete a mindfulness based
intervention will experience significantly greater psychological well-being, symptom
reduction, and greater changes in telomerase and cytokine activity than individuals who only
receive treatment as usual for their psoriasis.
The proposed research is a randomized, multi-site, blinded comparative study of
mindfulness-based cognitive therapy (MBCT), Mindfulness Based Self-compassion Therapy
(MBSCT), minimal-contact MBSCT, and treatment as usual (TAU) in patients with psoriasis.
Recruitment commenced in November 2013 and continued until March 2014. Participants were
recruited via the Department of Dermatology in St. Vincent's University Hospital. During
weekly dermatology clinics eligible participants were identified by medical members of the
Dermatology team and on expression of interest were referred to an Assistant Psychologist
for recruitment purposes. In addition participants were also recruited via an advertisement
placed in a national newspaper.
Eligible patients will be randomly assigned to TAU (n=25), MBCT (n=25), MBSCT (n=25), or
audio-guided MBSCT (n=25).
At Time 1 (pre intervention), participants will be required to give blood (a 50ml sample,
i.e., roughly 10 teaspoons), and complete self-report measures on the same day as beginning
the mindfulness programme. As it has previously been indicated that cells may be sensitive
to sudden changes in stress, mood and time of day (Epel, 2012), blood samples will always be
taken after completing the self-report measures and at a relatively standardized time, e.g.,
between 3-5pm. Care will be taken to ensure that conditions are relaxed across all
participants, and a 10 minute rest period between completing the questionnaires and giving
blood will be enforced. Bloods can be kept at room temperate for up to 24 hours and then
prepared for storage below 60 degrees Celsius until PBMC analysis is to be conducted after
all samples have been collected at Time 1 (post intervention).
At Time 2, six-months and twelve-months follow-up, participants will again be required to
give 50ml of blood and complete all self-report measures via an identical protocol, and
analysis will be conducted again accordingly. Telomerase will be assessed using a TRAPeze
EXCEL Telomerase Detection Kit. This will be complemented by flow cytometry analysis of
telomere length. Serum cytokines before and after treatment will be examined by ELISA. This
should give an indication of the effect of treatment on systemic inflammation. We will also
examine the ability of PBMC from patients to produce proinflammatory cytokines, including
IL-6, TNF, IL-1, and others associated with anxiety and depression. PBMC will be activated
with innate stimulus such as LPS/zymosan. The production of cytokines will be determined by
ELISA. Highly sensitive CRP is also a marker for psoriasis and will be assessed by ELISA to
give an indication of overall inflammation. In regards to self-report measures, the
following psychological scales will be used:
1. Hospital Anxiety and Depression Scale (HADS; Snaith & Zigmond, 1994)
2. Penn State Worry Questionnaire (PSWQ: Meyer, Miller, Metzger & Borkovec, 1990) 3 Fears
of Compassion Scales (Gilbert, 2009)
4. Five Facets of Mindfulness Questionnaire (FFMQ: Baer, Smith, Hopkins, Krietemeyer &
Toner, 2006) 5. World Health Organisation Quality of Life - BREF (WHO, 2004). 6. Dermatology
Quality of Life Index
Addressing our research question regarding the effectiveness of the mindfulness programs
involves a repeated-measures comparative group intervention design. 4x4 mixed-methods ANOVAs
will be used to assess pre, post and six/twelve month follow-up differences across the four
experimental conditions, with group as the independent variable and psychological experience
(e.g., depression, anxiety, worry, self compassion and mindfulness) or immunological
activity (e.g., PBMC telomerase and cytokines) as the dependent variables. Number of hours
per week practicing mindfulness during follow-up will be entered as a covariate. Effect
sizes and confidence intervals will be calculated post-hoc using G*Power in order to
facilitate ease of comparison between the study findings and other future studies and the
relevant field of literature. Bivariate Spearman's Correlations will be conducted to examine
the relationship between psychological variables and telomerase and cytokine activity on all
four testing occasions, respectively. Spearman's Correlations are chosen as a suitable
non-parametric correlation analysis given reports of telomerase as non-normally distributed
(e.g., Epel et al., 2010; Wolkowitz et al., 2012) and inspection of our own preliminary
data.
Data will be collected on four occasions; pre and post intervention and at six and twelve
months follow up.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |